Entering text into the input field will update the search result below

Spectranetics Corp. (SPNC) Posts Record Revenue and Significant Achievements for Q1

Apr. 27, 2011 2:21 PM ETSPNC
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2008

QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.

Medical device manufacturer Spectranetics Corp. today reported financial results for the quarter ended March 31, 2011, posting record revenue, FDA approval for trials of its EXCITE In-Stent Restenosis, regulatory approval for its Lead Locking Device in Japan, as well as other achievements for the quarter.

Revenue for the first quarter of 2011 increased 5 percent to $30.4 million compared with revenue of $29.0 million for the first quarter of 2010. The net loss for the first quarter of 2011 was $154,000, or $0.00 per share, compared with a net loss of $958,000, or $0.03 per share, in the first quarter of 2010. The net loss in the first quarter of 2010 included $353,000 in special items.

“Our performance in the first quarter reflected meaningful progress on the key initiatives that support our plan to accelerate revenue growth while establishing profitability in 2011. We delivered sequential growth in Vascular Intervention revenue and 14 percent revenue growth over the prior year in Lead Management – which is consistent with the financial objectives we outlined earlier this year,” Jason D. Hein, senior vice president of Sales, Marketing and Business Development stated in the press release.

Hein also noted the company’s placement of 41 laser systems with new customers during the first quarter of 2011, a sales level the company hasn’t reached in nearly three years. Hein said Spectranetics expects the laser systems to continue to contribute to improving revenue throughout the rest of the year.

Spectranetics also affirmed its previously provided outlook, without revision, and maintained its primary focus for 2011 of improving revenue growth while establishing profitability. Revenue is anticipated to be within the range of $122.5 million to $126.5 million, a 4-7 percent increase over 2010 revenue.

To improve manufacturing efficiencies in 2012 and beyond, the company said it plans on implementing several important initiatives, with a focus on marketing and sales.

“It remains our key objective to return to sustained double-digit revenue growth in 2012. Our strategy to achieve this is centered on marketing and sales execution to capitalize on the continued expansion of our addressable markets, new product introductions in 2012, international growth, particularly in Europe and Japan, and a renewed focus on clinical research as demonstrated by the planned initiation of the EXCITE ISR randomized clinical trial this quarter,” Shar Matin, senior vice president of Operations, Product Development, and International, stated.

For more information visit spectranetics.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.